A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Yunyi Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, Molecular Science and Biomedicine Laboratory and Aptamer Engineering C…. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, G-Quadruplexes, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Bladder cancer (BC) is a highly aggressive malignant tumor affecting the urinary system, characterized by metastasis and a poor prognosis that often leads to limited therapeutic success. This study aims to develop a novel DNA aptamer for the diagnosis and treatment of BC using a tissue‐based systematic evolution of ligands by an exponential enrichment (SELEX) process. By using SELEX, this work successfully generates a new aptamer named TB‐5, which demonstrates a remarkable and specific affinity for nucleolin (NCL) in BC tissues and displays marked biocompatibility both in vitro and in vivo. Additionally, this work shows that NCL is a reliable tissue‐specific biomarker in BC. Moreover, according to circular dichroism spectroscopy, TB‐5 forms a non‐G‐quadruplex structure, distinguishing it from the current NCL–targeting aptamer AS1411, and exhibits a distinct binding region on NCL compared to AS1411. Notably, this study further reveals that TB‐5 activates NCL function by promoting autophagy and suppressing the migration and invasion of BC cells, which occurs by disrupting mRNA transcription processes. These findings highlight the critical role of NCL in the pathological examination of BC and warrant more comprehensive investigations on anti‐NCL aptamers in BC imaging and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, Molecular Science and Biomedicine Laboratory and Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan, 410082, Ch…
- Department of Urology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine. Changsha, Hunan, 410013, China.
- Department of Neurosurgery and Neuroscience Institute, Baylor Scott & White Health, Temple, TX, 76508, USA.
- Department of Pathology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine. Changsha, Hunan, 410013, China.
- Department of Medical Education, Texas A&M University School of Medicine, College Station, TX, 77843, USA.
- Department of Pharmaceutical Sciences, Texas A&M University School of Pharmacy, College Station, TX, 77843, USA.
ORCID-Profile: Erxi Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
Zitieren
APA
Liu, Y., Hu, B., Pei, X., Li, J., Qi, D., Xu, Y., Ou, H., Wu, Y., Xue, L., Huang, J. H., Wu, E., & Hu, X. (2023). A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300791
Vancouver
Liu Y, Hu B, Pei X, Li J, Qi D, Xu Y, et al. A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300791
BibTeX
@article{Liu2023,
author = {Liu, Yunyi and Hu, Bei and Pei, Xiaming and Li, Juan and Qi, Dan and Xu, Yuxi and Ou, Hailong and Wu, Yatao and Xue, Lei and Huang, Jason H and Wu, Erxi and Hu, Xiaoxiao},
title = {A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300791}
}
EUVIMED